Lidings’ Associate Julia Kuzmenko Speaks at ONLINE PHARMA ADVANCE CONFERENCE
May 27th 2020 Julia Kuzmenko, Associate in Lidings’ Corporate and M&A practice, will take part in ONLINE PHARMA ADVANCE CONFERENCE organized by Business Summit of Future.
May 27th 2020 Julia Kuzmenko, Associate in Lidings’ Corporate and M&A practice, will take part in ONLINE PHARMA ADVANCE CONFERENCE organized by Business Summit of Future.
The new review of the most notable antitrust disputes in Life Sciences in Russia and CIS.
Federal law No 123-FZ sets a legal framework in Moscow for the development and implementation of artificial intelligence (AI) technologies. The experimental legal framework is established for five years starting from 1 July 2020.
The coronavirus outbreak (hereinafter referred to as COVID-19) served as a trigger for a targeted effort to assess and manage the possible effects of COVID-19.
According to art. 38 of the Law on fundamental healthcare principles the software used for medical purposes has a legal status of medical device. Therefore, market turnover of such software in Russia is allowed only after software is registered before the Federal Service for Surveillance in Healthcare (Roszdravnadzor).
On March 3, 2020, the Russian Government introduced to the State Duma the Draft Law on amendments to the Russian Civil Code, namely, article 1360.1.
Chambers and Partners Europe has announced the results of its annual research of the leading legal advisors. Lidings is traditionally highly recommended for Dispute Resolution, Corporate and M&A, and Life Sciences advice in Russia.
The year 2019, which continued the trend of rapid and numerous changes in healthcare regulations, was rich on expectations, events and legislative proposals aiming to reverse pharmaceutical industry: medical drugs labeling, reform of price determination, new procedure of entry into drugs civil circulation, amendments to regulatory framework of the Eurasian Economic Union, etc. This trend is likely to continue in 2020 as well.
The new review of the most notable patents disputes in Life Sciences in EAEU, CIS and Eastern Europe.
The site uses cookie technology to ensure optimal performance, analyze usage and improve user experience. By continuing to use the site, you consent to the placement of cookies on your device on the terms set out in the Privacy Policy.
To ensure optimal performance, analyze usage and improve user experience, the website may use web analytics systems (including Yandex.Metrica), which may place cookies on your device.
By continuing to use the website, you agree to the use of these technologies and the placement of cookies. You can delete cookies from your device through your browser settings and you can block the placement of cookies, however, in doing so, some website features may not be available due to the engine's technological limitations.
You can find more information in the Privacy Policy.